Resources & Information

Jun 14 2019

Board to draft FAQs on CBD products

Comments:   comments  Print Friendly Version  |   Share this item
In response to increased questions from licensees and the public regarding the appropriate clinical use of Cannabidiol (CBD) products, the Policy Committee of the Board will develop FAQs to address the most-raised questions and concerns. The Board has decided not to pursue a formal position statement on use of CBD products at this time.

 No Comments on this article

 Post a comment on this article
Please do not include links to external websites in your comment. Please limit comments to no more than 300 words. The NCMB reserves the right to edit comments to meet the length limit. Abusive or profane remarks and personal attacks will not be published. The editor will make every effort to review and post comments in a timely fashion.